Every material Form 8-K Edgewell Personal Care has filed with the SEC since August 06, 2024, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Edgewell Personal Care said LaTanya Langley will become Chief Administrative and Legal Officer and Corporate Secretary effective October 1, 2026, and will leave her Chief People Officer role on the same date. The filing states there are no changes to her compensation tied to these role changes.
Role change effective October 1, 2026, determined by the company on September 17, 2026
Langley will no longer serve as Chief People Officer as of October 1, 2026
No change to Langley's compensation in connection with the role changes
Edgewell reported fiscal third-quarter 2026 results for the quarter ended June 30, 2026. Net sales rose 1.7% to $570.1 million and adjusted EPS was flat at $0.72, while GAAP diluted EPS fell to $0.26 from $0.46. The company narrowed its full-year adjusted EPS range to $1.80 to $2.00 with the midpoint unchanged, but lowered its GAAP EPS outlook to flat to $0.20 and raised its expected restructuring-related charges to about $92 million.
Third-quarter net sales were $570.1 million, up 1.7%; organic net sales rose 1.1%, with North America up 3.0% and International down 1.4%.
Adjusted EPS was $0.72, unchanged from the prior year; GAAP diluted EPS was $0.26 versus $0.46.
Full-year adjusted EPS outlook narrowed to $1.80 to $2.00 from $1.70 to $2.10; GAAP EPS outlook lowered to flat to $0.20 from flat to $0.40.
The Board declared a quarterly dividend of $0.15 per share, payable October 8, 2026 to holders of record on September 9, 2026.
Edgewell Personal Care said Paul R. Hibbert will leave his role as Chief Supply Chain Officer effective June 1, 2026, and that Anthony Freve will succeed him in that role on the same date. The filing does not describe the reasons for the change, and the company is not reporting financial figures in this filing.
Paul R. Hibbert will no longer serve as Chief Supply Chain Officer, effective June 1, 2026; the company made this determination on May 20, 2026.
Hibbert is eligible for payments and benefits under the Company's Executive Severance Plan.
Anthony Freve will join Edgewell as Chief Supply Chain Officer, effective June 1, 2026, according to an announcement on May 26, 2026.
Edgewell reported fiscal second-quarter 2026 results, excluding the divested Feminine Care business. Net sales rose 0.6% to $519.5 million, but organic net sales fell 2.4% and adjusted EPS declined to $0.60 from $0.69. The company cut its full-year GAAP EPS outlook to flat to $0.40 from $0.55 to $0.95 because of higher restructuring and legal costs, while keeping its adjusted EPS outlook at $1.70 to $2.10.
Q2 net sales $519.5 million, up 0.6%; organic net sales down 2.4%
GAAP diluted EPS $0.09 vs. $0.43 a year earlier; adjusted EPS $0.60 vs. $0.69
FY2026 GAAP EPS outlook lowered to flat to $0.40; expected restructuring charges raised to about $90 million from $65 million
Quarterly dividend of $0.15 per share declared, payable July 9, 2026 to holders of record June 10, 2026
Edgewell reported first-quarter fiscal 2026 results with continuing-operations net sales of $422.8 million, up 1.9%, but a wider loss of $0.63 per diluted share from continuing operations versus $0.21 a year earlier. The company also completed the sale of its Feminine Care business for $340 million and now reports its outlook on a continuing-operations basis, which shows lower adjusted EPS and EBITDA ranges than the prior consolidated outlook because Feminine Care is removed.
Continuing-operations net sales were $422.8 million, up 1.9%; organic net sales decreased 0.5%.
Adjusted EPS was $(0.16) versus $(0.10) a year earlier; GAAP loss per diluted share was $(0.63) from continuing operations and $(1.41) including discontinued operations.
Fiscal 2026 adjusted EPS outlook is $1.70 to $2.10 on a continuing basis, versus $2.15 to $2.55 previously; the company says the full-year outlook for continuing operations is unchanged from its prior outlook.
Expected pre-tax restructuring and related charges for fiscal 2026 rose to approximately $65 million from $49 million.
Edgewell Personal Care closed the sale of its Feminine Care segment to Essity on February 2, 2026, receiving approximately $340 million in cash, subject to post-closing adjustments. The company plans to use the net proceeds mainly to pay down its U.S. revolving credit facility, and its pro forma filing estimates a loss on disposal and goodwill impairment of $42.1 million net of tax, which the company says may differ materially from the final figure.
Closing date was February 2, 2026; the company received about $340 million in cash from Essity, subject to adjustments for inventory, indebtedness and other items.
Pro forma filing shows $140.0 million outstanding on the revolving credit facility as of September 30, 2025, assumed to be repaid with sale proceeds.
Estimated loss on disposal and goodwill impairment of $42.1 million, net of tax, based on September 30, 2025 balances; the goodwill impairment alone was $37.4 million.
Transition services agreement with Essity covers accounting, IT, quality assurance, operations, supply chain and sales for at least one year.
Edgewell Personal Care reported fourth-quarter and fiscal 2025 results on November 13, 2025, with a fourth-quarter GAAP net loss of $30.6 million after a $51.1 million goodwill impairment tied to its Feminine Care business. Fiscal 2025 GAAP EPS was $0.53, down from $1.97, and the company gave fiscal 2026 guidance that excludes the planned $340 million sale of Feminine Care to Essity.
Q4 net sales were $537.2 million, up 3.8%, but the company posted a GAAP net loss of $30.6 million, or $0.66 per diluted share, versus net income of $8.8 million a year earlier.
Q4 included a non-cash goodwill impairment charge of $51.1 million for the Feminine Care reporting unit.
Fiscal 2025 net sales were $2,223.5 million, down 1.3%, and GAAP diluted EPS was $0.53 versus $1.97 in fiscal 2024.
Fiscal 2026 adjusted EPS is expected at $2.15 to $2.55, compared with fiscal 2025 adjusted EPS of $2.52; the outlook excludes the $340 million Feminine Care divestiture to Essity.
Edgewell Personal Care agreed on November 12, 2025 to sell its Feminine Care segment to Essity for $340 million in cash, subject to customary adjustments. The closing is expected in the first quarter of calendar 2026, pending regulatory approvals, and the company expects the sale to reduce its adjusted EPS and adjusted EBITDA on an annualized basis, net of transition service income.
Buyer: Essity Aktiebolag (publ); consideration is $340 million in cash, subject to adjustments for inventory, indebtedness and other items
Expected closing in the first quarter of calendar 2026; the outside date is May 12, 2026, with extensions to as late as November 12, 2026
Company expects an annualized impact of approximately $0.40 to $0.50 in adjusted EPS and $35 million to $45 million in adjusted EBITDA, net of transition services income
Net proceeds, after taxes and transaction costs, are intended primarily to strengthen the balance sheet; the company would receive a $15 million termination fee in certain circumstances
Edgewell Personal Care said its Chief Operating Officer, Daniel Sullivan, will resign effective October 1, 2025, to pursue another opportunity. The company will not fill the COO role and will instead use four regional hubs that report directly to the CEO, which the company says is meant to streamline operations.
Daniel J. Sullivan informed the company of his resignation on August 29, 2025; it takes effect October 1, 2025.
The COO position will not be replaced.
Four regional hubs (North America, Europe, Asia and Latin America) will report directly to CEO Rod Little, alongside the CFO and Chief Supply Chain Officer.
The company announced the change in a press release dated September 5, 2025 (Exhibit 99.1).
Edgewell Personal Care reported third-quarter fiscal 2025 net sales of $627.2 million, down 3.2%, with adjusted EPS of $0.92 versus $1.22 a year earlier. The company lowered its full-year fiscal 2025 outlook, including adjusted EPS of about $2.65 versus a prior range of $2.85 to $3.05, citing weak Sun Care seasons, tariffs and foreign exchange, which points to lower profit and cash generation for shareholders this year.
Q3 net sales were $627.2 million, down 3.2%; organic net sales fell 4.2% and North America organic sales fell 8.0%.
Q3 GAAP diluted EPS was $0.62 versus $0.98, and adjusted EPS was $0.92 versus $1.22 in the prior year quarter.
FY2025 adjusted EPS is now expected to be about $2.65 (previously $2.85 to $3.05); GAAP EPS is now about $1.73 (previously $2.09 to $2.29).
FY2025 free cash flow is now expected to be about $80 million (previously $130 million to $140 million); the board declared a $0.15 quarterly dividend payable October 8, 2025.
Edgewell Personal Care reported second-quarter fiscal 2025 net sales of $580.7 million, down 3.1% from the prior year, and GAAP diluted EPS of $0.60 versus $0.72. The company lowered its full-year fiscal 2025 outlook, including GAAP EPS of $2.09 to $2.29 (previously $2.54 to $2.74) and free cash flow of $130 million to $140 million (previously $185 million), which weighs on shareholder returns.
Q2 net sales $580.7 million, down 3.1%; organic net sales down 1.5%
GAAP diluted EPS $0.60 vs $0.72 a year earlier; adjusted EPS $0.87 vs $0.88
Full-year adjusted EPS now $2.85 to $3.05, versus previously towards the lower end of $3.15 to $3.35
Full-year free cash flow now $130 million to $140 million, down from $185 million; six-month operating cash flow was negative $70.5 million
Edgewell reported first-quarter fiscal 2025 net sales of $478.4 million, down 2.1%, and a GAAP loss of $0.04 per diluted share, versus earnings of $0.09 a year earlier. The company lowered its full-year GAAP EPS outlook to $2.54 to $2.74 from $2.59 to $2.79, citing foreign currency changes, and said adjusted EPS will be toward the lower end of its $3.15 to $3.35 range. Shareholders also voted at the February 6, 2025 annual meeting, re-electing all ten director nominees and approving the auditor and executive pay proposals.
Net sales were $478.4 million versus $488.9 million a year earlier; organic net sales decreased 1.3%.
GAAP diluted EPS was $(0.04) versus $0.09; adjusted EPS was $0.07 versus $0.24, including a $0.17 unfavorable currency impact.
Full-year fiscal 2025 GAAP EPS outlook was lowered to $2.54 to $2.74 from $2.59 to $2.79; adjusted EPS is now expected toward the lower end of $3.15 to $3.35.
At the February 6, 2025 annual meeting, all ten director nominees were elected and PricewaterhouseCoopers LLP was ratified as auditor.
Edgewell Personal Care reported fourth-quarter and fiscal 2024 results for the year ended September 30, 2024, and gave a fiscal 2025 outlook. Fourth-quarter net sales fell 3.1% and GAAP diluted EPS dropped to $0.17 from $0.58, while full-year net sales rose 0.1% and adjusted EPS rose 18%. The fiscal 2025 outlook calls for adjusted EPS of $3.15 to $3.35, which would be growth from $3.05, but the weak quarter and higher restructuring charges weigh on near-term results.
Q4 fiscal 2024 net sales were $517.6 million, down 3.1%; GAAP diluted EPS was $0.17 versus $0.58 a year earlier
Fiscal 2024 net sales were $2,253.7 million, up 0.1%; GAAP diluted EPS was $1.97 versus $2.21, and adjusted EPS was $3.05, up 18%
Fiscal 2025 outlook: adjusted EPS of $3.15 to $3.35 and organic net sales growth of approximately 1% to 3%
Quarterly cash dividend of $0.15 per share declared October 31, 2024, payable January 8, 2025
Edgewell Personal Care's board increased its size from 10 to 11 members and elected Stephanie Stahl as a director effective September 10, 2024, filling the new seat. Stahl will serve on the Audit Committee and the Human Capital and Compensation Committee, and her term runs to the 2025 annual meeting. The filing discloses no financial results, and the change is an administrative board addition.
Board expanded from 10 to 11 members, effective September 10, 2024
Stephanie Stahl joins the Audit Committee and Human Capital and Compensation Committee
Stahl's term expires at the 2025 Annual Meeting of Shareholders
Stahl is a Senior Advisor to Boston Consulting Group and serves on the boards of Carter's, Dollar Tree and Newell Brands
Edgewell Personal Care named Daniel Sullivan Chief Operating Officer and Francesca Weissman as Chief Financial Officer effective December 1, 2024, and said North America president Eric O'Toole will step aside under a separation agreement effective November 15, 2024. The changes were announced alongside third-quarter fiscal 2024 results, in which the company said it raised its fiscal 2024 Adjusted EBITDA and Adjusted EPS outlook.
Daniel J. Sullivan appointed Chief Operating Officer effective August 6, 2024; he remains CFO until December 1, 2024.
Francesca Weissman becomes CFO effective December 1, 2024, succeeding Sullivan.
The company raised its fiscal 2024 Adjusted EBITDA and Adjusted EPS outlook; the filing does not state the new figures.
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Edgewell Personal Care filing is on SEC EDGAR ↗. 8-K briefs of other companies →